{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-011411","form_type":"8-K","ticker":"ADGM","cik":"0002006986","company_name":"Adagio Medical Holdings, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.800745+00:00","generated_at":"2026-05-17T14:03:28.896141+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adagio Medical Q2 2025 net loss $3.9M; FULCRUM-VT enrollment at 85%","bullets":["Net loss narrowed to $3.9M ($0.26 basic EPS) from $5.7M in Q2 2024; revenue figure not disclosed.","Cash and equivalents of $8.2M as of June 30; cash burn reduced via corporate prioritization.","FULCRUM-VT pivotal study enrollment surpassed 85% of 206 patients; completion expected H2 2025.","First-in-human PARALELL PFCA results published in Journal of Cardiovascular Electrophysiology.","R&D expense down 31% to $2.0M; SG&A down 29% to $2.4M year-over-year."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-011411","json":"https://secwatch.observer/filing/0001558370-25-011411.json","markdown":"https://secwatch.observer/filing/0001558370-25-011411.md","text":"https://secwatch.observer/filing/0001558370-25-011411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006986/000155837025011411/0001558370-25-011411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006986/000155837025011411/adgm-20250813x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:03:28.896141+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}